Raloxifene, a selective estrogen receptor modulator, has beneficial estrogen agonist effects on bone and cardiovascular risk factors and estrogen antagonist effects on the breast and uterus. Limited clinical data have shown a sustained decrease in total cholesterol, low-density lipoprotein cholesterol, and homocysteine levels; an elevated homocysteine level is an independent risk factor for atherosclerosis. All of these studies were conducted in relatively young populations of women (mean age, 52-54 years). Raloxifene does not affect hot flushes, a major immediate symptom of menopause. This drug may therefore be useful in older women to prevent osteoporosis and cardiovascular disease. The aim of this clinical study was to evaluate the effects of raloxifene on plasma lipids and homocysteine in older women.
Scheda prodotto non validato
Scheda prodotto in fase di analisi da parte dello staff di validazione
|Titolo:||Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women|
|Citazione:||DE LEO, V., LA MARCA, A., Morgante, G., Lanzetta, D., Setacci, C., & Petraglia, F. (2001). Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 184(3), 350-353.|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto:
|Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women..pdf||Abstract||NON PUBBLICO - Accesso privato/ristretto||Administrator Richiedi una copia|